Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elasomeran - Moderna Therapeutics/National Institute of Allergy and Infectious Diseases

Next Previous
X
Search
Drug Profile

Elasomeran - Moderna Therapeutics/National Institute of Allergy and Infectious Diseases

Alternative Names: COVID-19 Vaccine Moderna; Moderna COVID-19 Vaccine; mRNA-1273; mRNA-1273 SARS-CoV-2 vaccine; SARS-CoV-2 RNA vaccine - Moderna Therapeutics; SARS-CoV-2 vaccine - Moderna Therapeutics/National Institute of Allergy and Infectious Diseases; SPIKEVAX; SPIKEVAX-X; SPIKEVAX-XBB.1.5; TAK-919

Latest Information Update: 17 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Moderna Therapeutics; National Institute of Allergy and Infectious Diseases
  • Developer Leiden University Medical Center; Moderna Therapeutics; National Institute of Allergy and Infectious Diseases; Regeneron Pharmaceuticals; Takeda
  • Class COVID-19 vaccines; RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed COVID 2019 infections
  • Phase III Human papillomavirus infections

Most Recent Events

  • 17 Jul 2024 Moderna's mRNA respiratory vaccine portfolio and Spikevax® market licensed to Mitsubishi Tanabe Pharma Corporation in Japan
  • 14 Jun 2024 Moderna Therapeutics completes the phase II/III trial in COVID-2019 infections (In adolescents, Prevention) in USA and Dominican Republic (IM) (NCT04649151)
  • 04 Jun 2024 Moderna submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2024-2025 formula, targeting the SARS-CoV-2 variant JN.1
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top